Profile data is unavailable for this security.
About the company
Jiangsu gdk Biotechnology Co Ltd is a biopharmaceutical company engaged in the research, development, production, and sales of human vaccines. The Company’s main product is a tetravalent influenza virus split vaccine, which is mainly used to prevent influenza caused by two influenza A virus strains and two influenza B virus strains. The Company's research products also include a variety of human vaccines for the prevention of epidemic colds, rabies, chickenpox, shingles, and pneumonia. The Company distributes its service within the domestic market.
- Revenue in CNY (TTM)33.39m
- Net income in CNY-128.83m
- Incorporated2008
- Employees451.00
- LocationJiangsu GDK Biotechnology Co LtdNo. 12 Yujin RoadTAIZHOU 225300ChinaCHN
- Phone+86 52 386205860
- Fax+86 52 386200152
- Websitehttp://www.gdkbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shaanxi Kanghui Pharmaceutical Co Ltd | 676.54m | -33.28m | 1.17bn | 952.00 | -- | 1.23 | -- | 1.73 | -0.3332 | -0.3332 | 6.77 | 9.51 | 0.3477 | 2.87 | 3.56 | 710,646.30 | -3.16 | -0.1562 | -4.44 | -0.1991 | 26.58 | 40.00 | -9.10 | -0.4907 | 0.6901 | -0.3569 | 0.3665 | 95.15 | 36.92 | 12.37 | 58.52 | -- | 66.95 | -- |
| Shanghai Serum Bio-Technology Co Ltd | 192.49m | 37.23m | 1.31bn | 321.00 | 35.31 | 1.21 | -- | 6.83 | 0.3441 | 0.3441 | 1.78 | 10.05 | 0.1689 | 0.9282 | 6.82 | 599,656.40 | 3.27 | 10.43 | 3.32 | 10.84 | 75.08 | 80.54 | 19.34 | 32.57 | 50.03 | -- | 0.0119 | 64.93 | 9.14 | 5.67 | -39.54 | -1.62 | 13.07 | -- |
| Jiangsu gdk Biotechnology Co Ltd | 33.39m | -128.83m | 1.32bn | 451.00 | -- | 0.9759 | -- | 39.44 | -1.04 | -1.04 | 0.2686 | 10.95 | 0.0193 | 0.4185 | 0.1529 | 74,034.57 | -7.45 | 3.30 | -8.73 | 4.84 | 51.14 | 75.56 | -385.83 | 12.58 | 3.20 | -- | 0.048 | 32.60 | -57.74 | -- | -270.88 | -- | 54.07 | -- |
| Shanghai Shen Lian Biomedical Corp | 307.69m | 13.44m | 1.61bn | 380.00 | 119.73 | 1.08 | -- | 5.23 | 0.0327 | 0.0327 | 0.7493 | 3.62 | 0.1927 | 0.9355 | 1.06 | 809,719.50 | 0.6798 | 5.39 | 0.7187 | 5.84 | 66.12 | 77.45 | 3.53 | 25.48 | 6.16 | -- | 0.0008 | 38.49 | -8.25 | 1.85 | -48.41 | -18.49 | 10.47 | -- |
Data as of Jul 26 2024. Currency figures normalised to Jiangsu GDK Biotechnology Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
2.43%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Orient Securities Asset Management Co. Ltd.as of 31 Dec 2023 | 412.27k | 0.96% |
| China Asset Management Co., Ltd.as of 31 Dec 2023 | 325.50k | 0.76% |
| Golden Trust Sinopac Fund Management Co., Ltd.as of 31 Dec 2023 | 132.70k | 0.31% |
| Huashang Fund Management Co., Ltd.as of 31 Dec 2023 | 50.16k | 0.12% |
| Harvest Fund Management Co., Ltd.as of 31 Dec 2023 | 42.83k | 0.10% |
| E Fund Management Co., Ltd.as of 31 Dec 2023 | 34.02k | 0.08% |
| Manulife TEDA Fund Management Co., Ltd.as of 31 Dec 2023 | 20.20k | 0.05% |
| Oriental Alpha Fund Management Co. Ltd.as of 31 Dec 2023 | 9.29k | 0.02% |
| HFT Investment Management Co., Ltd.as of 31 Dec 2023 | 8.50k | 0.02% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 4.98k | 0.01% |
More ▼
Data from 31 Dec 2023 - 24 Jul 2024Source: FactSet Research Systems Inc.
